Significance of changes in FGF23 levels in childhood primary nephrotic syndrome and children who progress to end‑stage renal disease

Liu,Ding; Yang,Fang; Zhang,Sui; Guo,Zhiqiang; Peng,Shuting

doi:10.3892/etm.2023.12089

Significance of changes in FGF23 levels in childhood primary nephrotic syndrome and children who progress to end‑stage renal disease

Authors:
- Ding Liu
- Fang Yang
- Sui Zhang
- Zhiqiang Guo
- Shuting Peng
View Affiliations

Affiliations: Department of Pediatrics, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China
Published online on: June 30, 2023 https://doi.org/10.3892/etm.2023.12089
Article Number: 390
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibroblast growth factor 23 (FGF23) is an important phosphaturic hormone, yet few studies have focused on FGF23 in children with primary nephrotic syndrome (PNS) and children who progressed to end‑stage renal disease (ESRD). This cross‑sectional study investigated the significance of changes in FGF23 levels in childhood PNS and children who progressed to ESRD. Of the 41 children included in the study, 17 had PNS with proteinuria and normal renal function (PNS group), 4 had ESRD (ESRD group), and 20 were healthy (control group). Following corticosteroid treatment, patients with PNS and proteinuria entered the remission phase. Serum levels of FGF23, phosphate, parathyroid hormone (PTH), 25‑hydroxyvitamin D (25‑OH‑D), and calcium were measured. It was found that FGF23 levels in the PNS and ESRD groups were higher than those in the control group, while serum 25‑OH‑D levels were lower. Serum PTH levels increased significantly in the ESRD group. In the control group, FGF23 levels were negatively correlated with serum PTH and positively correlated with serum 25‑OH‑D. FGF23 levels were positively correlated with serum calcium and corrected calcium levels in children with PNS during the remission phase. Increased FGF23 levels in children with PNS, particularly in children who progressed to ESRD. It was also confirmed that serum FGF23 levels begin to rise in children with PNS prior to Stage 1 chronic kidney disease. These findings indicated that increased FGF23 levels may be associated with the progression and severity of nephrosis in children, and that serum FGF23 levels were useful for early detection of abnormal mineral metabolism in children with PNS.

View Figures

View References

1	Eddy AA and Symons JM: Nephrotic syndrome in childhood. Lancet. 362:629–639. 2003.PubMed/NCBI View Article : Google Scholar
2	Shi XM, Liu BN, Zhong XH, Wang F and Ding J: Epidemiology of chronic kidney disease in children. Zhonghua Er Ke Za Zhi. 57:721–724. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
3	United States Renal Data System: 2018 USRDS annual data report: ESRD among children, adolescents, and young adults (EB/OL) 2018.
4	Aggarwal A, Yadav AK, Ramachandran R, Kumar V, Kumar V, Sachdeva N, Khandelwal N and Jha V: Bioavailable vitamin D levels are reduced and correlate with bone mineral density and markers of mineral metabolism in adults with nephrotic syndrome. Nephrology (Carlton). 21:483–489. 2016.PubMed/NCBI View Article : Google Scholar
5	Takashi Y and Fukumoto S: FGF23 beyond phosphotropic hormone. Trends Endocrinol Metab. 29:755–767. 2018.PubMed/NCBI View Article : Google Scholar
6	Kurosu H and Kuro-O M: The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol. 299:72–78. 2009.PubMed/NCBI View Article : Google Scholar
7	Edmonston D and Wolf M: FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 16:7–19. 2020.PubMed/NCBI View Article : Google Scholar
8	Perwad F, Zhang MY, Tenenhouse HS and Portale AA: Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 293:F1577–F1583. 2007.PubMed/NCBI View Article : Google Scholar
9	Meir T, Durlacher K, Pan Z, Amir G, Richards WG, Silver J and Naveh-Many T: Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 86:1106–1115. 2014.PubMed/NCBI View Article : Google Scholar
10	Bai X, Miao D, Li J, Goltzman D and Karaplis AC: Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 145:5269–5279. 2004.PubMed/NCBI View Article : Google Scholar
11	Razzaque MS and Lanske B: The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol. 194:1–10. 2007.PubMed/NCBI View Article : Google Scholar
12	Liu S and Quarles LD: How fibroblast growth factor 23 works. J Am Soc Nephrol. 18:1637–1647. 2007.PubMed/NCBI View Article : Google Scholar
13	Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H and Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 16:2205–2215. 2005.PubMed/NCBI View Article : Google Scholar
14	Stubbs J, Liu S and Quarles LD: Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. J Semin Dial. 20:302–308. 2010.PubMed/NCBI View Article : Google Scholar
15	Park SY, Jeong KH, Moon JY, Lee SH, Ihm CG, Rhee SY, Woo JT, Oh IH and Lee TW: The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients. Clin Exp Nephrol. 14:239–243. 2010.PubMed/NCBI View Article : Google Scholar
16	Figge J, Jabor A, Kazda A and Fencl V: Anion gap and hypoalbuminemia. Crit Care Med. 26:1807–1810. 1998.PubMed/NCBI View Article : Google Scholar
17	van Husen M, Fischer AK, Lehnhardt A, Klaassen I, Möller K, Müller-Wiefel DE and Kemper MJ: Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int. 78:200–206. 2010.PubMed/NCBI View Article : Google Scholar
18	Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M and Cochat P: The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 95:1741–1748. 2010.PubMed/NCBI View Article : Google Scholar
19	de Seigneux S, Courbebaisse M, Rutkowski JM, Wilhelm-Bals A, Metzger M, Khodo SN, Hasler U, Chehade H, Dizin E, Daryadel A, et al: Proteinuria increases plasma phosphate by altering its tubular handling. J Am Soc Nephrol. 26:1608–1618. 2015.PubMed/NCBI View Article : Google Scholar
20	Yadav AK, Ramachandran R, Aggarwal A, Kumar V, Gupta KL and Jha V: Fibroblast growth factor 23 in untreated nephrotic syndrome. Nephrology (Carlton). 23:362–365. 2018.PubMed/NCBI View Article : Google Scholar
21	Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, et al: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 305:2432–2439. 2011.PubMed/NCBI View Article : Google Scholar
22	Trautvetter U, Jahreis G, Kiehntopf M and Glei M: Consequences of a high phosphorus intake on mineral metabolism and bone remodeling in dependence of calcium intake in healthy subjects-a randomized placebo-controlled human intervention study. Nutr J. 15:1–11. 2015.PubMed/NCBI View Article : Google Scholar
23	Siomou E, Challa A, Printza N, Giapros V, Petropoulou F, Mitsioni A, Papachristou F and Stefanidis CJ: Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol. 26:1105–1114. 2011.PubMed/NCBI View Article : Google Scholar
24	Wesseling-Perry K, Tsai EW, Ettenger RB, Jüppner H and Salusky IB: Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: A role for FGF-23. Nephrol Dial Transplant. 26:3779–3784. 2011.PubMed/NCBI View Article : Google Scholar
25	Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, et al: Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 289:F1088–F1095. 2005.PubMed/NCBI View Article : Google Scholar
26	Cancela AL, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV, Cuppari L, Jorgetti V, Carvalho AB, Canziani ME, et al: Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract. 117:c74–c82. 2011.PubMed/NCBI View Article : Google Scholar
27	Lanske B and Razzaque MS: Molecular interactions of FGF23 and PTH in phosphate regulation. Kidney Int. 86:1072–1074. 2014.PubMed/NCBI View Article : Google Scholar
28	Galitzer H, Ben-Dov IZ, Silver J and Naveh-Many T: Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77:211–218. 2010.PubMed/NCBI View Article : Google Scholar
29	Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S and Serra AL: Secreted Klotho and FGF23 in chronic kidney disease stage 1 to 5: A sequence suggested from a cross-sectional study. Nephrol Dial Transplant. 28:352–359. 2013.PubMed/NCBI View Article : Google Scholar
30	Sato KA, Gray RW and Lemann J: Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Lab Clin Med. 99:325–330. 1982.PubMed/NCBI